These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36493397)

  • 1. Biosimilars for immune-mediated inflammatory diseases: a managed care perspective.
    Evans C; Gibofsky A; Strand V
    Am J Manag Care; 2022 Nov; 28(12 Suppl):S234-S239. PubMed ID: 36493397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence.
    Strand V; Evans C; Gibofsky A
    Am J Manag Care; 2022 Nov; 28(12 Suppl):S217-S226. PubMed ID: 36493395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars: From Production to Patient.
    Sheridan M; Massich M; Ashourian N
    J Infus Nurs; 2024 Jan-Feb 01; 47(1):19-29. PubMed ID: 38211611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
    Patel D; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Biosimilars in Oncology.
    Camacho LH
    Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.
    Manolis CH; Rajasenan K; Harwin W; McClelland S; Lopes M; Farnum C
    J Manag Care Spec Pharm; 2016 Sep; 22(9 Suppl):S3-9. PubMed ID: 27579939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
    Shubow S; Sun Q; Nguyen Phan AL; Hammell DC; Kane M; Lyman GH; Gibofsky A; Lichtenstein GR; Bloomgarden Z; Cross RK; Yim S; Polli JE; Wang YM
    Clin Pharmacol Ther; 2023 Jan; 113(1):37-49. PubMed ID: 36251545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems.
    Kvien TK; Patel K; Strand V
    Semin Arthritis Rheum; 2022 Feb; 52():151939. PubMed ID: 35027243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars might not measure up to health plan expectations.
    Reinke T
    Manag Care; 2012 Oct; 21(10):12-3. PubMed ID: 23156071
    [No Abstract]   [Full Text] [Related]  

  • 16. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in the Treatment of Retinal Disease in the United States.
    Vakharia PS; Eichenbaum DA; Baumal CR
    Ophthalmic Surg Lasers Imaging Retina; 2023 Jun; 54(6):362-366. PubMed ID: 37222553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing oncology biosimilars to minimize the economic burden associated with cancer treatment: managed care considerations.
    Liu Y
    Am J Manag Care; 2021 Aug; 27(14 Suppl):. PubMed ID: 34403576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.